Lilly Asia Ventures
About
Lilly Asia Ventures Lilly Asia Ventures is a biomedical venture capital firm. Fund VII closed at its $700M hard cap in 2024, with total AUM exceeding $1.2B across 6 funds. Fund VI was $1.35B ($900M core plus $450M opportunity vehicle). The firm was originally associated with Eli Lilly but now operates as an independent biomedical specialist. The tri-geography model covers Shanghai (China HQ), Hong Kong (Asia hub), and Palo Alto (US operations). Focus areas span biotechnology (drug discovery/deve
Industries
Stage focus
Series ASeries B+
Geography
ChinaUS
Raising from Lilly Asia Ventures?
I've worked with founders across the industrial stack. If Lilly Asia Ventures is on your list, I can help you map the introduction path, sharpen the narrative, and run a tight process.
Talk to Dan